Survival in multiple myeloma has improved significantly with the advent of novel, more potent immunotherapies, including CAR ...

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, ...

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...

Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...

Incidentally discovered vertebral fractures are common on scans in general population, but the absolute risk for MM in such ...

The phase 3 AQUILA study showed a 63.1% progression-free rate at 5 years with daratumumab versus 40.8% with active monitoring ...

AbbVie (ABBV) was granted FDA orphan designation for a treatment of multiple myeloma, according to a post to the agency’s website.Pick the best ...